October 6, 2014
Executive Vice President Katsuya Nishino JCR Pharmaceuticals says that will work to grow its cell-based drug JR-031 for the treatment of acute graft versus host disease (GVHD) into a new profit pillar if the drug is approved. Executive Vice President...read more